Your browser doesn't support javascript.
loading
Local Intracoronary Infusion of Glycoprotein IIb/IIIa Inhibitors via a Perfusion Catheter versus Intracoronary Guiding Catheter Injection during Primary Percutaneous Coronary Intervention: A Pilot Observational Study.
Zaki, Tarek; Labib, Salwa; El-Abbady, Maged; El-Kilany, Wael; Mortada, Ayman; Rashid, Tarek; Ragy, Hany; El-Itreby, Adel; Nammas, Wail.
Afiliação
  • Zaki T; Department of Cardiology, Faculty of Medicine, Ain Shams University.
  • Labib S; National Heart Institute, Cairo, Egypt.
  • El-Abbady M; National Heart Institute, Cairo, Egypt.
  • El-Kilany W; Department of Cardiology, Faculty of Medicine, Ain Shams University.
  • Mortada A; Department of Cardiology, Faculty of Medicine, Ain Shams University.
  • Rashid T; Department of Cardiology, Faculty of Medicine, Ain Shams University.
  • Ragy H; National Heart Institute, Cairo, Egypt.
  • El-Itreby A; Department of Cardiology, Faculty of Medicine, Ain Shams University.
  • Nammas W; Department of Cardiology, Faculty of Medicine, Ain Shams University.
Acta Cardiol Sin ; 33(3): 258-265, 2017 May.
Article em En | MEDLINE | ID: mdl-28559656
BACKGROUND: Glycoprotein IIb IIIa inhibitors improved short- and long-term outcome when added to primary percutaneous coronary intervention (PPCI) in patients with ST-segment-elevation myocardial infarction (STEMI). We hypothesized that intracoronary eptifibatide infusion via a perfusion catheter improves angiographic and clinical outcome of patients with STEMI undergoing PPCI, versus conventional intracoronary bolus injection. METHODS: Prospectively, we enrolled 80 patients with acute STEMI and thrombolysis in myocardial infarction (TIMI) thrombus grade ≥ 2. Patients were assigned to receive eptifibatide (180 µg) either via a dedicated coronary perfusion catheter (ClearWayTM) during PPCI (group I), or guiding catheter (group II). Assessment of TIMI thrombus grade, TIMI flow grade, and TIMI myocardial perfusion (TMP) grade was performed both at baseline and post- procedurally. The primary 'angiographic' endpoint was final TMP grade 0/1. The primary 'clinical' endpoint was a composite of cardiac death, non-fatal re-infarction, target vessel revascularization, and recurrent ischemia at 30-day follow-up. RESULTS: Mean age was 52.3 ± 8.9 years (17.5% females). Clearance of visible thrombus (TIMI thrombus grade 0) at final angiogram was more frequent in group I. Additionally, both final TIMI flow grade 3 and final TMP grade 3 occurred more frequently in group I. The primary angiographic endpoint was more frequent in group II versus group I (17.5% versus 0%, respectively, p = 0.001). The primary clinical endpoint was more frequent in group II (20% versus 0%, respectively, p = 0.003). CONCLUSIONS: In patients with STEMI, intracoronary eptifibatide infusion via a perfusion catheter during PPCI improved immediate angiographic outcome, and reduced clinical events at 30-day follow-up, versus bolus injection via the guiding catheter.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Acta Cardiol Sin Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Acta Cardiol Sin Ano de publicação: 2017 Tipo de documento: Article